Explore active and passive temperature-controlled shipping solutions and their impact on clinical trial supply, balancing cost, risk, and product integrity.
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Enabling The Rapid, Reproducible Manufacturing Of TranspoCART Cells
Learn how an innovative technology streamlines Transpocart cell production, making rapid and consistent manufacturing a reality for cell therapies.
-
Techniques For PEGylation Site Identification
Examine how our innovative methods enable the precise identification of PEGylation sites, unlocking deeper insights into the structure, stability, and function of biotherapeutics.
-
Challenges, Methods, And Solutions For Obtaining Optimal Starting Material
For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation for these therapies.
-
A Comparative Study Of Cryopreservation Media
This study compared two different cryopreservation mediums and the data highlights which is ideal for preserving the viability of different cell types, including Mesenchymal Stem and HEK-293 Cell Line.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
-
Off-Script FDA: How Smart Teams Pivot, Escalate, And Progress
Dr. Rachel Sherman, former Principal Deputy Commissioner of the FDA, explains the rules of engagement for working with today’s FDA.
-
Advancing Cell Therapy Manufacturing: Rapid Sterility Testing
The rapid sterility test kit used in the study was able to quickly detect bacteria and fungi in complex cell therapy product matrices, detecting six species listed in USP chapter <71>.
-
Simplify Your Bioprocess Development With Custom Buffers
Tailor your bioprocess for optimal cell growth, gene expression, and therapeutic production with custom buffers to ensure precise control over pH, ion concentrations, and nutrient availability.
-
Mycoplasma Testing In Monoclonal Antibody Production
Prevent costly disruptions in your bioproduction process. Discover how a PCR-based method can quickly detect the presence of mycoplasmas in raw materials, cell banks, and in-process and lot-release samples.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
NEWSLETTER ARCHIVE
- 02.14.26 -- Cell & Gene Best Of January
- 02.13.26 -- Strengthening Your Regulatory Path: Strategies For Compliance And Safety
- 02.13.26 -- Developing Itvisma For Broad-Range Treatment Of SMA With Dr. Norman Putzki
- 02.12.26 -- Why Your MVP And Its Evolution Matters To Manufacturing
- 02.11.26 -- Breakthroughs In Cell Research & Automation
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections